Bigbear Pharmaceutical·Medication Guide

• FDA Approves Verzenio (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with H

  FDA Approval AnnouncementINDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Verz···【Read More】

  Update: 2026-03-06Source: Haiou HealthViews: 73

• FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Bre

  FDA Approval AnnouncementINDIANAPOLIS, March 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Adm···【Read More】

  Update: 2026-03-06Source: Haiou HealthViews: 72

• Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer

  Study AnnouncementTHURSDAY, Oct. 23, 2025 -- A study published online Oct. 17 in the Annals of Oncology (coinciding with the annual meeting of the Eur···【Read More】

  Update: 2026-03-06Source: Haiou HealthViews: 73

• Side Effects and Precautions for Abemaciclib

  Common Side EffectsHematologic ToxicityNeutropenia may occur; regular complete blood count monitoring is required. Dose adjustment or treatment interr···【Read More】

  Update: 2026-03-06Source: Haiou HealthViews: 71

• What Is Abemaciclib Used For

  Abemaciclib is an oral targeted anticancer drug belonging to the CDK4/6 inhibitor class. It is mainly used for the treatment of hormone receptor‑posit···【Read More】

  Update: 2026-03-06Source: Haiou HealthViews: 76

• What other drugs may affect cabozantinib?

  Certain medications should not be used together due to safety concerns. Some drugs can alter the blood levels of others you are taking, which may incr···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• What should I avoid while taking cabozantinib?

  Grapefruit and grapefruit products may interact with cabozantinib and increase the risk of adverse side effects. Do not consume grapefruit products du···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• What if I overdose?

  Seek emergency medical help immediately or call the Poison Help line.【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• What if I miss a dose?

  Take the medication as soon as you remember. However, skip the missed dose if your next scheduled dose is in less than 12 hours. Do not take a double ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• Side Effects and Adverse Reactions of Cabozantinib

  Cabozantinib is a broad-spectrum anticancer drug with multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AXL, NT···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• Cabozantinib Dosage and Administration: Common Dosage and Dosage Adjustment

  Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• FDA Approves Cabozantinib (Cabometyx) for Previously Treated Patients with Advanced Neuroendocrine T

  On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• Detailed instructions for Cabozantinib: indications, dosage, side effects, and precautions

  Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• Cabozantinib (Cabometyx) Chinese instruction manual

  Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72

• The FDA has approved lorlatinib for the treatment of previously treated ALK-positive metastatic non

  On November 2, 2018, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved lorlatinib, a third-generation anaplastic lymphoma···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 72